Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

SAN DIEGO, April 8, 2008 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it initiated screening in a Phase 2b clinical trial of APD125 in patients with primary insomnia. APD125 is an oral drug candidate discovered by Arena with the potential to reduce insomnia symptoms and improve sleep maintenance and quality.

The Phase 2b trial of APD125 is a double-blind, randomized, placebo- controlled subjective study evaluating the efficacy and tolerability of APD125 in patients with primary insomnia characterized by difficulty maintaining sleep. The trial, which is expected to enroll a total of approximately 675 male and female patients in about 70 clinical sites in the United States, will evaluate two doses (20 mg and 40 mg) and placebo over 14 nights of treatment. The trial will evaluate standard subjective measurements of sleep, including change from baseline in subjective number of awakenings after sleep onset (sNAASO), which is the primary endpoint.

"We are very encouraged by the emerging profile of APD125. We believe APD125 has the potential to significantly improve sleep maintenance and quality for patients with insomnia without the potential for dependence or impairing psychomotor function," said Jack Lief, Arena's President and Chief Executive Officer. "Results from this trial are expected around year end, and we believe they will increase our understanding of APD125 while supporting ongoing partnership efforts."

In a Phase 2a trial, when compared to placebo, patients treated with APD125 achieved statistically significant improvements in objective measurements of sleep maintenance, or the ability to maintain sleep during the night after falling asleep, and sleep architecture. T
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013   Accuray Incorporated (Nasdaq: ... study results involving hundreds of prostate cancer patients ... most widely used form of prostate stereotactic body ... for a median of 5 years, and many ... percent of patients with low-risk and 90.7% of ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... point-of-care blood analysis systems, announced today that ... present at the Stifel Annual Dental & Veterinary Conference ... The conference will be held at Le Parker Meridien ... About Abaxis Abaxis develops, manufactures, ...
(Date:5/21/2013)... DIEGO , May 21, 2013 ... a secondary analysis of its double-blind, randomized, controlled ... is a gene therapy product designed to deliver ... exploratory analysis identified a more robust response to ... prior to treatment relative to those diagnosed 10 ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... Two Abstracts Accepted for ... 2008, BRIDGEWATER, N.J., Sept. 4 Aegerion ... treatment of,cardiovascular and metabolic disease, today announced the ... board of directors., Peter Garrambone,s career includes ...
... Long term follow up results from chronically infected Hepatitis C,patients strongly confirm and ... first to show a statistically significant and long-term ... pave the way and strongly support move into a second generation, vaccine ... ...
Cached Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4
(Date:5/21/2013)... paper recently published in the New England Journal ... at the University of Colorado School of Medicine finds ... can be used to identify individuals at risk for ... fairly common variant of the gene for mucin-5B, a ... by the bronchial tubes. While this variant of the ...
(Date:5/21/2013)... of Defense Serum Repository (DoDSR), University of Cincinnati (UC) ... bowel disease (IBD), which could help with earlier diagnosis ... symptoms. , This finding, the first of its kind ... presented via podium presentation by staff from Walter Reed ... being held May 18-21 in Orlando, Fla. , ...
(Date:5/21/2013)... New York (PRWEB) May 21, 2013 ... surgery robot lawsuit is nearing its conclusion in ... to Bloomberg.com, during closing statements yesterday, an attorney for ... alleging the company wanted to tie sales and services ... all the training to keep control of surgeons, to ...
(Date:5/21/2013)... May 21, 2013 Go Classy Tours, ... that they have redesigned their website featuring N ... pool, hot tubs, bars and dining. The website, which ... including sales and guest reviews, will now have a ... itself, including pages on culinary local recipes, flora and ...
(Date:5/21/2013)... While North Carolina is synonymous with golf, ... Brunswick Plantation & Golf Resort is synonymous with affordable ... 27 holes of "Top10" championship golf. , With ... the Top 10 from an industry expert ... task of selecting the course to play. Guests staying ...
Breaking Medicine News(10 mins):Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
... YORK, Oct. 6 In support of Breast Cancer Awareness ... ages with a collection of fashionable "pink" products. Touting ... of the American Cancer Society (ACS). , (Photo: ... Whether young or old, many of us have witnessed ...
... ... in the parts washing industry. Midbrook has extensive experience washing parts and equipment in a ... Washing facility to help a North American automotive parts supplier solve a de-rusting issue. ... (Vocus) October 6, 2009 -- ...
... ... factors when selecting a Medicare plan , ... Belleville, Ill. (Vocus) – People with disabilities have crucial healthcare ... a nationwide provider of Social Security disability representation and Medicare services. , , ...
... ... CSHL Fellow and Faculty Investigator, made major discoveries in telomere biochemistry and regulation ... Cold Spring Harbor, ... Carol Greider, Ph.D., has been named a Nobel Laureate, Cold Spring Harbor Laboratory President ...
... ... Australian Securities Exchange-listed oncology biotechnology company, announced today an AU$7,230,000 investment by SpringTree ... exclusive financial advisor to SpringTree,s general partner SpringTree Global Investors, LLC on the ... ...
... HEIGHTS, N.Y., Oct. 6 In an effort to build a ... are drilling nano-sized holes in computer-like chips and passing DNA strands ... genetic code. , View video: http://www.youtube.com/watch?v=pKi30ai35mU ... , For an ongoing conversation on this research ...
Cached Medicine News:Health News:This October Lady Foot Locker Is Fashioned for a Cause 2Health News:Midbrook Production Washing A Valuable Partner 2Health News:Midbrook Production Washing A Valuable Partner 3Health News:People with Disabilities Face Unique Healthcare Coverage Challenges, Allsup Says 2Health News:People with Disabilities Face Unique Healthcare Coverage Challenges, Allsup Says 3Health News:People with Disabilities Face Unique Healthcare Coverage Challenges, Allsup Says 4Health News:People with Disabilities Face Unique Healthcare Coverage Challenges, Allsup Says 5Health News:People with Disabilities Face Unique Healthcare Coverage Challenges, Allsup Says 6Health News:Cold Spring Harbor Laboratory's President Congratulates Alumna on Winning Nobel Prize 2Health News:KTA Capital Advises SpringTree Global Investors on an AU$7.2 Million Investment in HealthLinx Ltd 2Health News:IBM Research Aims to Build Nanoscale DNA Sequencer to Help Drive Down Cost of Personalized Genetic Analysis 2Health News:IBM Research Aims to Build Nanoscale DNA Sequencer to Help Drive Down Cost of Personalized Genetic Analysis 3Health News:IBM Research Aims to Build Nanoscale DNA Sequencer to Help Drive Down Cost of Personalized Genetic Analysis 4
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
This optimal design addresses low-cost, simple, non-invasive ankle distraction....
... Clinical Lab Accuracy The Q.E.D.® ... an accurate screen in place ... In clinical trials, saliva alcohol ... demonstrated high correlation to blood ...
ThyroTest by ThyroTec, Inc. is a rapid immunoassay, similar to a rapid pregnancy test. By using 2 drops of blood from a finger stick and 5 drops of diluent, a qualitative TSH level is inicated in min...
Medicine Products: